Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study - Moraly, Josquin; Rossignol, Julien; Rouzaud, Claire; Gabas, Thomas; Bouktit, Hassiba; Lhermitte, Ludovic; Canioni, Danielle; Fraitag, Sylvie; Bruneau, Julie; Barete, Stéphane; Suarez, Felipe; Ballul, Thomas; et al. (American journal of hematology, 2024)
Keywords: Adult; Aged; Aged, 80 and over; Allografts; Apoptosis; Cytarabine; Everolimus - adverse effects; Everolimus - therapeutic use; Female; France; Humans; Inhibitor drugs; Life Sciences; Life span; Male; Mast cells; Mastocytosis; Mastocytosis, Systemic - drug therapy; Middle Aged; MTOR Inhibitors - therapeutic use; Mutation; Pilot Projects; Proto-Oncogene Proteins c-kit - antagonists & inhibitors; Proto-Oncogene Proteins c-kit - genetics; Quality of life; Rapamycin; Sirolimus - adverse effects; Sirolimus - therapeutic use; Stem cell transplantation; TOR protein; TOR Serine-Threonine Kinases - antagonists & inhibitors; Treatment Outcome; Tryptase; France